Disclosed is an isolated anti-DLL4 antibody comprising six hypervariable region (HVR) sequences: (i) HVR-L1 comprising sequence A1-A11, wherein A1-A11 is RASQDVSTAVA (SEQ ID NO: 10) (ii) HVR-L2 comprising sequence B1-B7, wherein B1-B7 is SASFLYS (SEQ ID NO:11) (iii) HVR-L3 comprising sequence C1-C9, wherein C1-C9 is QQSYTGTVT(SEQ ID NO:18) (iv) HVR-H1 comprising sequence D1-D10, wherein D1-D10 is GFTFTDNWIS (SEQ ID NO:1) (v) HVR-H2 comprising sequence E1-E18, wherein E1-E18 is GYISPNSGFTYYADSVKG (SEQ ID NO:8) and (vi) HVR-H3 comprising sequence F1-F15, wherein F1-F15 is VYYCARDNFGGYFDY (SEQ ID NO:9). Also disclosed is the use of the antibody in the manufacture of a medicament for treating a tumor, cancer, or cell proliferative disorder.
